InvestorsHub Logo
Followers 3
Posts 582
Boards Moderated 0
Alias Born 01/19/2012

Re: None

Thursday, 07/19/2018 2:43:07 AM

Thursday, July 19, 2018 2:43:07 AM

Post# of 7807


Here's the list of drugs J&J plans to file for approval over the next four years that could hit that blockbuster threshold, including cancer and depression treatments:
•guselkumab - psoriasis (Filed for approval in 2016)
•sirukumab - rheumatoid arthritis (Filed for approval in 2016)
•apalutamide - pre-metastatic prostate cancer
•esketamine - treatment-resistant depression
•talacotuzumab - acute myeloid leukemia, a type of blood cancer
•erdafitinib - solid tumors
•niraparib - prostate cancer
•imetelstat - myelofibrosis, a bone marrow disorder
•pimodivir - influenza A
•lumicitabine - respiratory syncytial virus (RSV) infection
•JNJ-7922 - adjunctive treatment for major depressive disorder

http://www.businessinsider.com/johnson-and-johnson-blockbuster-drug-potentials-by-2021-2017-5
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GERN News